UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 879

Sortiert nach

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

Journal for immunotherapy of cancer, 2022-02, Vol.10 (2), p.e003844

2022

Volltextzugriff (PDF)

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Clinical cancer research, 2017-07, Vol.23 (14), p.3557-3565

2017

Volltextzugriff (PDF)

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

Journal of clinical oncology, 2020-06, Vol.38 (16), p.1797-1806

2020

Volltextzugriff (PDF)

A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy

Investigational new drugs, 2021-08, Vol.39 (4), p.1019-1027

2021

Volltextzugriff (PDF)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

Cancer, 2019-07, Vol.125 (14), p.2400-2408

2019

Volltextzugriff (PDF)

A urologic perspective on management of localized and metastatic RCC

Oncology (Williston Park, N.Y.), 2012-06, Vol.26 (6), p.537-537

2012

Volltextzugriff (PDF)

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

Blood, 2002-02, Vol.99 (4), p.1486-1488

2002

Volltextzugriff (PDF)

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.604-604

2023

Volltextzugriff (PDF)

A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS282-TPS282

2023

Volltextzugriff (PDF)

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4591-TPS4591

2021

Volltextzugriff (PDF)

Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.309-309

2021

Volltextzugriff (PDF)

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4618-TPS4618

2022

Volltextzugriff (PDF)

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.288-288

2022

Volltextzugriff (PDF)

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.197-197

2019

Volltextzugriff (PDF)

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4510-4510

2021

Volltextzugriff (PDF)

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.5006-5006

2020

Volltextzugriff (PDF)

Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4504-4504

2019

Volltextzugriff (PDF)

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in advanced clear cell renal cell carcinoma

Cancer, 2019-04, Vol.125 (14), p.2400-2408

2019

Volltextzugriff (PDF)

Pen of iron: american prose and the king james bible.

Alter, Robert

1, 2010

Volltextzugriff (PDF)

The Book of Job : Aesthetics, Ethics, Hermeneutics

1st edition., 2014

Volltextzugriff (PDF)

Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma

Journal of immunotherapy with emphasis on tumor immunology, 1994-08, Vol.16 (2), p.132

1994

Volltextzugriff (PDF)

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Nature (London), 2021-06, Vol.594 (7862), p.253-258

2021

Volltextzugriff (PDF)

The Literary Guide to the Bible

The Times Educational Supplement, 1988 (3736), p.27

1988

Volltextzugriff (PDF)

The Power of Antibody-Based Surveillance

The New England journal of medicine, 2020-10, Vol.383 (18), p.1782-1784

2020

Volltextzugriff (PDF)

The Rise of International Regime Complexity

Annual review of law and social science, 2018-10, Vol.14, p.329

2018

Volltextzugriff (PDF)

1 – 25 von 879

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(442)
Mit Volltextzugriff
(768)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma

A urologic perspective on management of localized and metastatic RCC

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A)

A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC)

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study

Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B)

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260)

Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in advanced clear cell renal cell carcinoma

Pen of iron: american prose and the king james bible.

The Book of Job : Aesthetics, Ethics, Hermeneutics

Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

The Literary Guide to the Bible

The Power of Antibody-Based Surveillance

The Rise of International Regime Complexity

Suchergebnisse filtern